Item 8.01 Other Events
On January 21, 2021, Adamis Pharmaceuticals Corporation ("Adamis" or the
"Company") issued a press release announcing that its SYMJEPI® (epinephrine)
Injection products are now available to members of the Walgreens Prescription
Savings Club program. A copy of the Company's press release is attached hereto
as Exhibit 99.1 is incorporated into this item by reference.
Forward Looking Statements
This Current Report on Form 8-K contains forward-looking statements within the
meaning of the Private Securities Litigation Reform Act of 1995. Such
forward-looking statements include those that express plans, anticipation,
intent, contingencies, goals, targets or future development and/or otherwise are
not statements of historical fact. These statements relate to future events or
future results of operations, including, but not limited to the following
statements: the company's beliefs concerning the commercialization of SYMJEPI
and its other products and product candidates; the extent of sales of SYMJEPI
resulting from the availability of the products within the Walgreens
Prescription Savings Club program; the company's beliefs concerning the ability
of its product to compete successfully in the market; and the company's beliefs
concerning the safety and effectiveness of SYMJEPI or its other products and
product candidates. These statements are only predictions and involve known and
unknown risks, uncertainties and other factors, which may cause Adamis' actual
results to be materially different from these forward-looking statements. You
should not place undue reliance on any forward-looking statements. There are no
assurances regarding the extent of sales of SYMJEPI products, or revenues to the
company, resulting from the availability of the products within the Walgreens
Prescription Savings Club program. Further, any forward-looking statement speaks
only as of the date on which it is made, and except as may be required by
applicable law, we undertake no obligation to update or release publicly the
results of any revisions to these forward-looking statements or to reflect
events or circumstances arising after the date of this Report. Certain of these
risks, uncertainties, and other factors are described in greater detail in
Adamis' filings from time to time with the SEC, which Adamis strongly urges you
to read and consider, all of which are available free of charge on the SEC's web
site at http://www.sec.gov. Except to the extent required by law, any
forward-looking statements in this Report speak only as the date of this Report,
and Adamis expressly disclaims any obligation to update any forward-looking
statements.
© Edgar Online, source Glimpses